We read with interest the article by Paulig and Prosiegel 1 concerning a patient initially diagnosed with amyotrophic lateral sclerosis (ALS), who had suffered from progressive swallowing difficulties ...

Background In the CLARITY AD study, lecanemab was shown to reduce markers of amyloid and slow cognitive decline at 18 months in early Alzheimer’s disease (AD). Here, we report the initial findings ...